No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 119.9x · 10Y median 334.2x · 25th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:10.659Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Canton Strategic Holdings Inc (CNTN) stock was $2.33 as of Oct 6, 2026, 10:05 AM EDT, down 0.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -19.9% · 3-year avg -67.9%/yr
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas.
Biotechnology · Red Bank, NJ
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-86.25
Revenue Est.
$1.50M
Last Quarter Results
EPS
$0.01
vs Estimate
N/A
Revenue
$1.50M
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CNTN | $179.31M | $2.33 | -0.21% | -19.85% | N/A | N/A | N/A |
| 2CUE | $178.56M | $24.58 | +0.90% | +11.33% | -42.42% | N/A | vs CNTN |
| 3CMPX | $177.22M | $0.98 | +2.45% | -73.87% | -22.79% | N/A | vs CNTN |
| 4DERM | $182.88M | $6.64 | -0.67% | -8.69% | N/A | N/A | vs CNTN |
| 5DTIL | $173.89M | $6.30 | -0.16% | +15.91% | -54.84% | N/A | vs CNTN |
| 6MDWD | $172.65M | $13.44 | -0.52% | -21.32% | -9.04% | -12.86% | vs CNTN |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$2.33
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-86.25 | $-86.25 | $-86.25 | 1 |
| Quarter ending Dec 2026 | $-60.00 | $-60.00 | $-60.00 | 1 |
| Quarter ending Mar 2027 | $-18.75 | $-18.75 | $-18.75 | 1 |
| Quarter ending Jun 2027 | $-15.00 | $-15.00 | $-15.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
| FY 2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.50M | $1.50M | $1.50M | 1 |
| Quarter ending Dec 2026 | $1.50M | $1.50M | $1.50M | 1 |
| Quarter ending Mar 2027 | $1.50M | $1.50M | $1.50M | 1 |
| Quarter ending Jun 2027 | $1.50M | $1.50M | $1.50M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
